VasoMedical to Exhibit at ACC.15
WESTBURY, N.Y. – March 10, 2015 – VasoMedical, Inc. (VASO.OTC), a diversified medical technology company specializing in the design, manufacture and sale of non-invasive medical devices, including EECP® Therapy systems, the gold standard of external counterpulsation technology, today announced its participation in the American College of Cardiology's 64th Annual Scientific Session & Expo (ACC.15) on March 14-16, 2015 in San Diego, California. This will be the 20th consecutive year that VasoMedical has participated in this major cardiovascular event.
The ACC's Scientific Session & Expo is an annual meeting in which members of the ACC and medical professionals, both domestic and international, come together to share and discuss the latest developments in cardiovascular medicine. The ACC meeting this year will have over 13,000 professional attendees participating and more than 300 exhibitors signing up to exhibit at the three day conference. The main focus of ACC.15 is innovations in the prevention of cardiovascular disease.
VasoMedical will be exhibiting in booth #3733 in the San Diego Convention Center. The Company will be conducting demonstrations of its core technology, EECP® Therapy, its BIOXTM ambulatory patient monitoring products as well as the MobiCareTM Wireless patient monitoring system.
“As the largest congregation of cardiologists, cardiac surgeons and other cardiovascular healthcare professionals in the united States, the American College of Cardiology's annual scientific session represents an opportunity for VasoMedical to demonstrate its focus on innovation and its capabilities in product design to meet the clinical and economic challenges in healthcare today,” said Jun Ma, President and CEO at VasoMedical.
In addition, an abstract entitled “Patients that Respond to Enhanced External Counterpulsation Are at Decreased Risk for Major Adverse Cardiac Events And Have Increases in Endothelial Precursor Stem Cells” has been accepted for poster presentation (#1228-364) at the ACC.15 on Sunday, March 15, 2015 at 3:45 PM in Poster Hall B1. Dr. Joseph Tartaglia, the lead author of the abstract, was one of the first cardiologists to offer EECP® Therapy in the U.S.
Dr. Tartaglia stated, “EECP therapy has been demonstrated in the medical literatures to produce excellent outcomes in treating stable ischemic angina patients who are refractory to invasive procedures and medication.” He further commented, “our study sought to shed light on the question of whether the effect is purely from exercise training and if improvements in exercise capacity lead to permanent positive outcomes.”
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: VasoMedical Solutions, Inc., VasoMedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Michael J. Beecher